The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • INOVIQ (IIQ) confirms positive results during its testing for ovarian cancer
  • The company wrapped up its Ovarian Cancer 97 study, which was undertaken by the Centre for Clinical Research at The University of Queensland
  • The study confirmed the utility of EXO-NET for extracellular vesicle (EV) biomarker discovery, with over 90 per cent accuracy for the detection of early-stage ovarian cancer
  • The company says its next steps will include an analytical validation study to establish equivalence of the EV-based ovarian cancer test in plasma compared to serum from the same cohort of patients
  • INOVIQ climbs 13.9 per cent, trading at 69.5 cents at 3:06 pm AEDT

INOVIQ (IIQ) has confirmed positive results during its testing for ovarian cancer.

The company has now wrapped up its Ovarian Cancer 97 study, which was undertaken by the Centre for Clinical Research at The University of Queensland.

The study confirmed the utility of EXO-NET for extracellular vesicle (EV) biomarker discovery and generation of a multivariate index assay, with over 90 per cent accuracy for the detection of early-stage ovarian cancer.        

Data from 97 plasma samples, including ovarian cancer, benign and healthy controls, identified highly significant differences between the EV biomarker content of ovarian cancer and control samples.

Data showed a multivariate algorithm using selected EV biomarkers achieved 92 per cent accuracy for detection of early-stage ovarian cancers in an independent sample set.

“The OC97 study is the first milestone achieved in the collaboration with The University of Queensland to develop a world-first EV ovarian cancer screening test,” CEO Dr Leearne Hinch said.

“OC97 has successfully established that EXO-NET effectively isolates EV biomarkers from plasma and has identified additional informative biomarkers for inclusion in UQ’s OCRF7 ovarian cancer test.

The multivariate index assay (MIA) showed over 90 per cent accuracy for detection of early stage ovarian cancers, when the cancer can be more effectively treated and help save women’s lives.”

The company said its next steps will include an analytical validation study to establish equivalence of the EV-based ovarian cancer test in plasma compared to serum from the same cohort of patients.

INOVIQ climbed 13.9 per cent, trading at 69.5 cents at 3:06 pm AEDT.

IIQ by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Market closes the week on a high | 12 July 2024

The ASX200 closed up 0.9% to 7959 points. All sectors finished the day in the green…
ASX chart prices

Week 27 Wrap: ASX hits all time high; CBA shares’ two realities; US inflation hits 3% ahead of China plenum

The ASX200 ended the week at a fresh all time high. Can we hit 8,000pts by…
The Market Online Video

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Infini Resources (ASX:I88) has unveiled what it believes could be the highest ever soil sample uranium concentrations found in Newfoundland, Canada, at its
The Market Online Video

ASX Market Update: ASX hits new record on lower than expected US inflation | 12 July 2024

The ASX200 has claimed a new record, reaching above 7,950 points on the back of positive futures.